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ÖZET 
Amaç:   Bu çalışmada, terapötik plazma değişimi (TPD) ile tedavi ettiğimiz 
nöro-immünolojik olgulara ait 7 yıllık deneyimimizin sonuçları rapor edilmiştir. 
Yön tem : TPD uyguladığımız 91 olgunun (53 erkek, 38 kadın) medikal 
kayıtları geriye dönük olarak incelenmiştir.  
Bul gu lar: Tanısal olarak sınıflandığında, bu olguların 60’ının Guillain-Barre 
sendromu (GBS), 23’ünün Miyastenia Gravis (MG), 4’ünün ise kronik 
inflammatuar demiyelinizan polinöropati (KİDP) tanısıyla TPD aldığı 
görülmüştür. Birer olguya ise, polimiyozit, septik ensefalopati, akut dissemine 
ensefalomiyelit (ADEM) ve Opsoklonus-Myoklonus sendromu (OMS) 
tanılarıyla TPD uygulanmıştır.
GBS hastalarımızın %26,7’sinde tam düzelme, %61,7’sinde kısmi düzelme 
izlenmiş olup, disabilitesi yüksek %11,7 hasta solunum yetmezliği nedeniyle 
kaybedilmiştir. MG’li hastaların %13,4’ünde tedaviye rağmen ölüm, %78’inde 
tam klinik düzelme gözlenmiştir. KIDP’li 4 hastamızın üçünde total, birinde 
kısmi düzelme gözlenmiş, ADEM’li olgumuz TPD ile önce kısmen düzelmiş 
ancak tedaviden 2 ay sonra aspirasyon pnömonisine bağlı solunum 
yetmezliği nedeniyle kaybedilmiş, polimiyozitli olgumuzda kısmi, septik 
ensefalopati ve OMS’li hastalarımızda tam düzelme gözlenmiştir. TPE 
uygulamasında karşılaştığımız yan etkiler hipotansiyon, hipokalsemi ve anemi 
gibi hafif ve yönetilebilir düzeydedir. 
So nuç: Çalışmamızın sonuçları otoimmün kökenli nörolojik hastalıklarda 
TPE tedavisinin etkili ve güvenilir bir yöntem olduğunu göstermektedir  
(Nö rop si ki yat ri Ar fli vi 2014; 51: 63-68)
Anah tar ke li me ler: Terapötik Plazma Değişimi, Guillain-Barre sendromu, 
Kronik İnflammatuar Demiyelinizan Polinöropati, Miyastenia Gravis 
çıkar çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar 
çatışması bildirmemişlerdir.
ABS TRACT
ıntroduction: In this study, we report the results of our experience of therapeutic 
plasma exchange (TPE) for neuroimmunologic disorders performed at our hospital 
over a seven-year period.  
Met hods: We retrospectively reviewed the medical records of 91 patients (53 
male, 38 female) who had been treated at our center with TPE. 
re sults: 60 patients with Guillain-Barrè syndrome (GBS), 23 with myasthenia 
gravis (MG), 4 with chronic inflammatory demyelinating polyneuropathy (CIDP) 
and 1 patient each with polymyositis, septic encephalopathy, acute disseminated 
encephalomyelitis (ADEM) and Opsoclonus-Myoclonus syndrome (OMS) received 
TPE. 26.7% of GBS patient’s made complete recovery, 61.7% had partial recovery 
and 11.7% patients died due to respiratory failure. Despite our best efforts and 
effective TPE treatments, 13.4% of MG patients deceased, however, 78% had full 
recovery. Three patients with CIDP were discharged with full and 1 patient with 
partial recovery. The patient with ADEM had partial recovery with TPE at first, 
but deceased 2 months later due to pneumonia-related respiratory insufficiency. 
While, patient with polymyositis had slight-partial recovery, we obtained 
full recovery with TPE in septic encephalopathy and OMS patients. The side 
effects and complications of treatments with TPE, which included hypotension, 
hypocalcaemia and anemia, were mild and manageable. 
conc lu si on: The improvement rates were encouraging and we concluded 
that significant benefit can be achieved with TPE for the treatment of 
neuroimmunological disorders. (Arc hi ves of Neu ropsy chi atry 2014; 51: 63-68) 
Key words: Therapeutic Plasma Exchange, Guillain-Barre syndrome, Chronic 
Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis  
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Introduction 
Therapeutic plasma exchange (TPE) has been used to 
remove immunoglobulins and other immunologically active 
substances, such as complements or cytokines, from the 
blood for the treatment of neurologic diseases in which 
autoimmunity plays a major role (1). The number of diseases 
treated with TPE increases with further understanding 
of the etiopathogenesis of neurologic diseases and 
improved techniques. It is a standard treatment regimen 
for some neurologic diseases, such as GBS, MC and CIDP 
(2,3,4,5,6,7,8). In a recent report of the Therapeutics and 
Technology and Assessment Subcommittee of the American 
Academy of Neurology, TPE was established as an effective 
course of treatment for many diseases; it is offered in cases 
of severe acute inflammatory demyelinating polyneuropathy 
(AIDP)/GBS, in the short-term management of CIDP (Class I, 
Level A), and is probably effective and should be considered 
for mild AIDP/GBS (9). There have been some other case 
reports and small studies in which it was claimed that TPE 
might be effective for some other neurologic diseases such 
as multiple sclerosis (10), neuromyelitis optica (11), acute 
disseminated encephalomyelitis (ADEM) (12), Stiff-man 
syndrome (13), Bickerstaff’s encephalitis (14) and hemorrhagic 
leucoencephalitis (15). Additionally, it has been suggested 
that TPE may also be successful in treating complications 
of the central nervous system resulting from systemic 
hematologic diseases such as thrombocytopenic purpura 
(16). An alternative treatment option for TPE is intravenous 
immunoglobulin (IVIG), however, IVIG is very expensive and 
in many countries is not covered by insurance (17). Plasma 
exchange typically requires central venous access that can 
lead to severe complications such as thrombosis, septic 
infections or pneumothorax. However, TPE is a safe procedure 
for the treatment of appropriate neurological illnesses in a 
specialized unit with a high patient volume (9). 
Neurologic disorders constitute the largest group of 
indications for TPE and, the number is increasing due to 
growing knowledge of pathogenic relevance of auto-
antibodies. Although some traditional indications are 
supported by properly designed randomized trials, others 
are not. In order to determine the utility of plasmapheresis 
in different diseases, especially in rarely encountered 
diseases, we need more results. Therefore, we aimed to 
make contribution to the literature by reporting our results, 
considering other publications on this subject.
Methods
We reviewed the medical records of 91 neurologic patients 
who had been consecutively treated with TPE therapy between 
January 2004 and June 2011, in the Department of Neurology 
at Başkent University Faculty of Medicine, Adana Research 
and Practice Center. During this period, 457 procedures of 
TPE were applied to 91 patients with neurologic disorders. 
The medical records were analyzed for the patients’ 
demographic details (sex and age), types of neuroimmunologic 
diseases, treatment modalities, prognoses, and any 
complications of the treatment. 
Neurological indications included GBS, MG, CIDP, 
polymyositis, septic encephalopathy, OMS and ADEM. There 
were 38 female and 53 male patients. The mean age was 
51.1±16.8 years with a range of 17-80 years (Table 1).
All TPE procedures were done via central venous catheter. 
The device used in all procedures was COBE Spectra 
(Lakewood, Colorado, USA) which works with continuous 
flow. Total blood and plasma volume were calculated by using 
standard formulation. Albumin-saline, ISOHES, ringer lactate 
and fresh frozen plasma were selected as replacement fluids 
according to the patient’s clinical and laboratory parameters. 
The total protein, albumin and calcium levels of all patients 
were measured before and after each TPE therapy. TPE was 
given every other day for most of the patients and a total of 
1.51 plasma volumes were exchanged per cycle. The mean 
TPE session number was 5.06±1.73 and the mean plasma 
volume was 50 ml/kg for each cycle. 
For patients with GBS and CIDP, we considered a mean 
improvement in the disability grade, measured 4 weeks after 
the end of the TPE therapy and based on the 7-point Hughes 
Disability Grade Scale (18) and a mean improvement in the 
Osserman scale (19) for myasthenic patients, as the primary 
outcome measure. We have already been using the Hughes 
Disability Grading Scale for the monitoring of efficacy of TPE 
for the inflammatory neuropathy patients, the scores were 
taken from the patients’ files. In addition, for the resolution 
of crises in myasthenic cases, we considered the duration of 
ventilation, time needed for independent walking, residual 
disabilities, and death, 4 weeks after treatment as secondary 
outcome measures. We also recorded the complications due 
to TPE. The approvals for off-label treatments were used.
Table 1. Diagnostic and demographic details of the 
patients treated with plasmapheresis
diagnosis   number 
of the 
patients
Mean 
age±Sd 
Sex 
(Female/
Male)
GBS 60 52.5±15.86 27/33
CIDP 4 49.3±17 2/2
MG 
(prethymectomy)
9 41.1±18.8 5/4
MC 14 51.6±15.6 3/11
ADEM 1 28 0/1
Septic
Encephalopathy
1 18 1/0
Polymyositis 1 51 0/1
OMS 1 49 0/1
GBS: Guillain Barré Syndrome, CIDP: Chronic Inflammatory Demyelinating Polyneuropathy, 
MG: Myasthenia Gravis, MC: Myasthenic Crisis, ADEM: Acute Disseminated 
Encephalomyelitis, OMS: Opsoclonus Myoclonus Syndrome 
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Results
GBS
The clinical diagnoses, the disability levels accordingly 
(18), and demographic features of the patients are summarized 
in Table 1 and 2. Twenty (33.3%) patients with GBS were 
not able to walk without assistance (Hughes 3), 25 patients 
(41.7%) were confined to a wheelchair or bed (Hughes 4), 
and 15 patients (25%) were in need of mechanical ventilation 
(Hughes 5). In all cases, TPE therapy was started within 10 
days after the onset of the disease. Table 3 summarizes 
the prognoses of these patients. In a four-week therapy 
period, during which all patients also received physical 
therapy and rehabilitation, 16 patients (26.7%) experienced 
complete recovery (≥4 degree improvement in grades), 37 
patients (61.7%) showed partial improvement (2-3 degree 
improvement in grades) and, when they were discharged, 
all of them were able to walk unaided or with little support. 
Seven GBS patients died (11.7%) with higher initial Hughes 
scores and respiratory failure. Among deceased patients from 
GBS, only 4 completed all the TPE sessions, 2 received only 1 
session, and 1 received 2 sessions. Two of deceased patients 
suffered from acute motor sensory axonal neuropathy 
(AMSAN), and 5 of them had AIDP. Fifteen of 60 GBS patients 
were classified as acute motor axonal neuropathy (AMAN), 
among which there were no deaths. 
CIDP
All of the CIDP patients required assistance with walking 
when first admitted to hospital and they either had not 
benefitted from at least 3-month corticosteroid treatment, 
or it had caused marked blood glucose elevation. However, 
after TPE therapy, all of them improved significantly. One of 
the patients was already on a cyclic TPE treatment since 2 
years; he had not benefitted from steroid treatment which he 
had received at another center for 1 year, but we were able 
to achieve significant improvement with 5 cycles of TPE in 
one of his exacerbation periods. Another male patient, who 
was initially treated with IVIG successfully,  had to be treated 
with cyclic TPE due to insurance problems and marked 
improvement was recorded. One female patient was treated 
with methylprednisolone for 3 months with no improvement, 
but prominent recovery was achieved with 6 cycles of TPE. 
A second female patient was treated for 3 exacerbations of 
CIDP with TPE due to steroid-related severe blood glucose 
elevation and unresponsiveness to IVIG in the 6th months of 
her diagnosis. Additionally, all the patients with CIDP were 
on azathioprine treatment (2 mg/kg/day). 
MG
Twenty tree patients with MG were treated with TPE therapy; 
9 (F/M: 4/5) received TPE therapy during the preparation stages 
of thymectomy, and 14 (F/M: 3/11) were treated for either MC’s 
(6) or severe bulbar signs and myasthenia-related respiratory 
insufficiency (8). The patients with bulbar signs were treated 
with TPE to quickly stabilize the clinical outlook and to 
prevent deterioration of their clinical status because of newly 
started 1 mg/kg prednisone daily. Their Osserman gradings are 
shown on Table 4. Three patients died in myasthenic group; 
1 due to infection in the early post-thymectomy period (day 
4); 2 due to MC. Last 2 died in their second crises and, they 
had needed 10 sessions of TPE for the resolution of their first 
crises: One of them had congenital lung anomaly, and critical 
illness neuropathy was observed in the second. In addition, 
second crises of these patients were more severe and they 
died in the initial 1-2 sessions of TPE.
Table 2. Demographics, electrophysiological subtypes 
(for the cases with GBS) and Hughes grading’s of the 
cases with demyelinating polyneuropathy treated with 
TPE  
number 
of the 
patients 
Aıdp
n=35
AMAn
n=15
AMSAn
n=10 
cıdp
n=4
F/M 16/19 8/7 3/7 2/2
Mean Age 52.5±13.2 52.6±21.1 58.1±19.2 49.3±17
Grade 0 0 0 0 0
Grade 1 0 0 0 0
Grade 2 0 0 0 1
Grade 3 13 4 3 3
Grade 4 14 7 5 0
Grade 5 8 4 2 0
Grade 6 0 0 0 0
GBS: Guillain Barre Syndrome, TPE: Therapeutic Plasma Exchange, AIDP: Acute 
Inflammatory Demyelinating Polyneuropathy, AMAN: Acute Motor Axonal Neuropathy, 
AMSAN, Acute Motor Sensory Axonal Neuropathy, CIDP: Chronic Inflammatory 
Demyelinating Polyneuropathy
Table 3. Details of the prognoses of cases after the treatment with TPE
diagnosis Aıdp AMAn AMSAn cıdp Mg AdeM polimyositis Se oMS
No of patients 35 15 10 4 23 (9 patients with 
prethymectomy)
1 1 1 1
Full recovery
Partial covery
Exitus
12
18
5
3
12
0
1
7
2
1
3
0
9
3 
2
0
0
1
0
1
0
1
0
0
1
0
0
AIDP: Acute Inflammatory Demyelinating Polyneuropathy, AMAN: Acute Motor Axonal Neuropathy, AMSAN: Acute Motor Sensory Axonal Neuropathy, CIDP: Chronic Inflammatory Demyelinating 
Polyneuropathy, MG: Myasthenia Gravis, ADEM: Acute Demyelinating Encephalomyelitis, SE: Septic Encephalopathy, OMS: Opsoclonus Myoclonus Syndrome
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The targeted neurological deficits of the remaining 12 
patients were improved by TPE therapy. Nine had a complete 
recovery, while the bulbar signs were resolved in 3 patients 
with MC. None of our myasthenic patients received IVIG 
treatment. 
In addition, 7 patients from the prethymectomy group 
and 7 patients from MC group were found to be positive 
for AchR antibodies, and 1 patient in the MC group was 
positive for anti-titin. The mean duration of the disease was 
estimated to be 12 months in the MC patients and 18 months 
in the prethymectomy group. 
Polymyositis
A 51-year-old man has complained severe quadriparesis 
since 6 months. Elevation of creatine kinase and 
pseudomyotonic discharges on electromyography were 
shown. Muscle biopsy revealed necrotizing myopathy. We 
performed 7 sessions of TPE therapy on alternate days, but 
the patient achieved only slight improvement in a 4-week 
period. IVIG therapy also proved ineffective. However, 
the patient made a complete recovery after a 3-month 
azathioprine therapy with 2.5 mg /kg/day. 
Septic Encephalopathy
An 18-year-old girl showing a confused state of mind was 
examined in the intensive care unit. She had facial cellulitis 
and it had progressed into septic state. She made a full 
recovery with 3 cycles of TPE.  
OMS
A 49-year-old man with rapid, dysrhythmic and 
uncoordinated involuntary eye movements and ataxia by 
4-day was hospitalized. It is known that most adults with 
OMS have neoplastic, infectious, metabolic, or idiopathic 
etiologies. We excluded the possibility of a cancer with 
appropriate investigations. After the treatment failed with 
steroids (1 g/day for 5 days), we got full recovery by 5 
courses of TPE on alternate day. 
ADEM
A 28-year-old man was referred with 2-month duration 
of severe quadriparesis, he was unresponsive to 7-day high-
dose methylprednisolone pulses and also, IVIG (35 gram/day) 
for 5 days had been failed. He received 7 sessions of TPE 
on alternate days, and underwent respiratory physiotherapy. 
Marked improvement was achieved in breathing problems, 
and the patient was removed from mechanical ventilation. He 
was discharged as quadriplegic but, 2 months after he was 
hospitalized with pneumonia due to aspiration, and he died.
Results
Thirty-one of our 91 patients made a complete recovery, 
and 49 showed partial improvement. Despite our best efforts, 
11 of our patients died. 
During the procedures, no patient mortality was related 
to the TPE therapy. A total of 7 patients; 3 GBS patients, 
2 MG patients and 2 CIDP patients experienced adverse 
events. In our patients, only one of them had tetany due 
to hypocalcaemia during apheresis, and the procedure 
was stopped until the calcium levels were restored. Mild 
and manageable complications such as hypotension and 
hypocalcaemia were also observed in these 7 patients.  
Discussion
It is believed that cross reaction between the antibodies 
against a microbial agent and the neuronal tissues cause GBS 
(20). GBS is a major cause of acute neuromuscular paralysis 
with an annual incidence of 1.3-2 per 100 000 throughout the 
world (21), and is treated both medically and supportively. 
Medical treatment methods include IVIG and plasmapheresis, 
although TPE was introduced as a possible alternative 
treatment in 1978 (22), and was shown to offer significant 
benefit by a randomized trial published in 1985 (23). In a 
study comparing the effects of TPE, IVIG, and a combined 
regimen of TPE followed by IVIG, no difference was found in 
terms of clinical outcome between the three groups (24). The 
Cochrane systematic meta-analysis reported that TPE was the 
only treatment for GBS found to be superior to supportive 
treatment (25). Furthermore, TPE was more beneficial when 
applied within the first 7 days of the disease, although it 
was still effective when performed within the first month 
(25). Sixteen (26.7%) of our GBS patients made a complete 
recovery, 37 (61.7%) had partial recovery improvement with 
2-3 degrees on the Hughes scale after TPE at the end of first 
month, and 7 (11.7%) died. However, no other treatment 
modalities have been adequately tested in these deceased 
GBS patients. Yucesan et al. reported that their all 6 patients 
with GBS improved with TPE treatment and their recovery 
rate was 100% (7). In our experience, the recovery rate of 
GBS patients was 88.3%, but our study population was 10 
times larger with 60 GBS patients. In the report of Van Doorn 
et al. related to GBS patients treated with TPE, 3-10% of 
patients died and 20% were unable to walk after 6 months 
(26). In our study group, 11.7% of GBS patients deceased; 
these proportions are similar with the literature. 
Overall, we may say that TPE is effective for GBS and 
improved therapeutic strategies are urgently needed for the 
unresponsive cases. When we followed TPE with IVIG therapy, 
significant improvement was seen in the GBS patients, and 
in particular in those with AMAN. However, a study by the 
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome 
Table 4. Osserman grading’s of the patients with 
Myasthenia Gravis
numbers of patients      n=23
F/M       7/16
Mean age (year)    46.1±17.1
Grade 1        5
Grade 2A        2
Grade 2B        1
Grade 3        9
Grade 4        6
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Trial Group showed that IVIG and TPE were equally effective 
in the treatment of GBS, although sequential application did 
not yield any additional benefit (24). However, in the Miller-
Fischer variant of GBS, neither IVIG nor TPE is recommended; 
owing to the benign nature of the disease, the regimens are 
not found to be superior to supportive therapy alone (27). 
We considered scores of 1-3 in the Hughes Scale as showing 
good prognosis, and higher scores were accepted as poor 
prognostic factors. 
In CIDP, efficacy of TPE was confirmed in two small 
controlled trials (4,5). The use of TPE is recommended in any 
patient with CIDP who cannot walk unaided or has a more 
severe deficit (Class I, Level A) (9), who has compromised 
respiratory function, whose disease cannot be controlled 
adequately with two months of corticosteroid therapy with a 
dosage of 1-1.5 mg/kg every other day (8). Recently, due to 
a change in policy implemented by the Ministry of Health in 
Turkey, social security did not cover the IVIG treatment for 
CIDP patients and thus, those patients who did not respond 
to corticosteroids had to be treated by regular TPE’s for 
a while. We achieved significant improvement with our 4 
CIDP patients using TPE therapy. Although there were not 
enough patients to determine how beneficial TPE is in the 
treatment of patients with CIDP, we suggest that it might 
be an effective treatment choice for CIDP patients who do 
not respond well to corticosteroids and have unpredictable 
blood glucose elevation.  
MG is a relatively rare disease with a variable prevalence 
of 5 to 15/100.000 (28,29,30). About 15% to 20% of patients 
with MG experience MC at some point in the course of their 
disease. Current statistics still report a mortality rate of 
3% to 8% related to MC’s, despite newer treatment and 
intense medical care (30). Infections, including lower and 
upper respiratory tract infections, are responsible for at 
least 70% of MCs (31). MC is traditionally defined as an 
acute respiratory failure due to worsening MG, requiring 
admission to an intensive care unit (32,33). The basis of the 
action of plasmapheresis in MC is that it rapidly eliminates 
the pathological antibodies via mechanical separation or 
more recently, by immunoadsorption or double filtration 
techniques (34,35,36). A standard course in myasthenia 
exacerbation entails 5 to 6 exchanges on alternating days 
utilizing 2 to 4 L per exchange (34,35). Although there is 
inadequate data to evaluate the use of plasmapheresis in 
the treatment of MC or the prethymectomy period in MG, in 
the last report of the American Academy of Neurology, TPE 
appears to be just as beneficial as IVIG therapy in patients 
with MG (9). In addition, a Cochrane review compared the 
efficacy of IVIG with plasma exchange, other treatments and 
placebo; it was concluded that IVIG and TPE are equally 
effective on MC (36). The efficacy of TPE in MG varies 
from 55 to 100% in various reports (37,38,39). In addition, 
although it was shown that TPE was optimal when it was 
performed 4 sessions in one course, the number of sessions 
can be changed according to the patients’ clinical response. 
For advanced MG, a daily schedule was reported to be more 
effective than an alternate-day regimen. Although plasma 
exchange procedures are mostly done via plasmapheresis, 
in clinical practice, immunoadsorption can also be used, and 
may in fact be a superior method in MC cases (40). We 
treated 18 MCs of 14 patients with TPE, and 16 of these 
crises were resolved, 2 died in the initial TPE sessions of 
their second crises. In the report of Yucesan et al., all of the 
30 MG patients treated with TPE improved. It is important to 
note that, one of our deceased myasthenics had congenital 
lung problems and critical illness neuropathy was observed 
in the second and, during their first crises, 10 sessions of 
TPE was needed for considerable improvement. The efficacy 
of TPE in MG varies from 55% to 100% in various reports and 
our results were similar to that in the literature. Co-morbid 
diseases may increase the mortality.  
The side effects of plasmapheresis include pneumothorax, 
hypotension, hypocalcaemia and septicemia, pulmonary 
embolism, bleeding from the catheter region or obstruction, 
anemia, thrombocytopenia, and impairment of coagulation 
parameters (2). We recorded hypotension, hypocalcemia and 
anemia in our patients. These results were similar to those 
of the study by Yucesan et al., which was also carried out 
in Turkey. They also reported a case with septicemia due to 
venous catheter used for TPE. From these points of view, it 
can be said that TPE is a safe procedure when performed 
in experienced units, and may be preferable for controlling 
symptoms in the early stages of neuroimmunological disorders 
in which autoimmunity plays a major role in the pathogenesis. 
Despite all clinical observations, further prospective 
research are necessary to establish the role of plasmapheresis 
in mild AIDP/GBS, long-term management of CIDP, treatment 
of neuropathy associated with IgM gammopathy, MCs and 
the prethymectomy period of MG, and in fulminant central 
nervous system demyelinating diseases.
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